EAN 2026: New Fintepla data in Dravet Syndrome and LGS
Researchers at the Brno Epilepsy Centre in Czechia announced data from a retrospective, single-centre observational study evaluating the efficacy and …
Post
-
-
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme
Eli Lilly and Regeneron are in the first slate of drugmakers included in a new US scheme to expedite the …
-
Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger
New Jersey-based biotech, Talawar Therapeutics and JATT II Acquisition have joined forces through a definitive business combination agreement – creating …
-
Anixa Biosciences secures Korean patent for breast cancer vaccine
Anixa Biosciences has secured a patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology. The …
-
Three years on: How is the industry coping with Annex 1?
Three years after its release, the revised EU GMP Annex 1 stands as an industry watershed, redefining sterile medicine manufacturing. …
-
Eli Lilly and Innovent agree Verzenios commercialisation deal in China
Eli Lilly and Company has entered into an agreement with Innovent Biologics for the commercialisation of Verzenios (abemaciclib) in mainland …
-
EAN 2026: New Fintepla data in Dravet Syndrome and LGS
Researchers at the Brno Epilepsy Centre in Czechia announced data from a retrospective, single-centre observational study evaluating the efficacy and …
-
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme
Eli Lilly and Regeneron are in the first slate of drugmakers included in a new US scheme to expedite the …
-
Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger
New Jersey-based biotech, Talawar Therapeutics and JATT II Acquisition have joined forces through a definitive business combination agreement – creating …
-
Anixa Biosciences secures Korean patent for breast cancer vaccine
Anixa Biosciences has secured a patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology. The …
-
Three years on: How is the industry coping with Annex 1?
Three years after its release, the revised EU GMP Annex 1 stands as an industry watershed, redefining sterile medicine manufacturing. …
-
HLTH Europe 2026: Healthcare implementation key amid European innovation rush
As healthcare players from Europe and further afield continue to produce potentially game-changing healthcare innovations, attendees at HLTH Europe 2026 …
-
Zymeworks agrees to buy Theravance Biopharma for $929m
Canadian biotechnology company Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m …
-
EMA backs market rollback of rare disease drug Tavneos over data concerns
The European Medicines Agency (EMA) has recommended that marketing authorisation for Tavneos (avacopan) be revoked due to question marks over …
-
Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
Three months after Biogen announced its $5.6bn buyout of rare disease specialist Apellis Pharmaceuticals, the former has decided to cull …
